Type 1 diabetes (T1D) patients had a lower serum MOTS-c level than did healthy controls. Furthermore, MOTS-c reduced T cell activation by alleviating T cells from the glycolytic stress in T1D patients, suggesting therapeutic potential.
[Cell Reports]
6445218
{6445218:NTM5D3YG}
apa
50
1
165047
https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/
